|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
GB9710807D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
PL211786B1
(pl)
|
1999-08-17 |
2012-06-29 |
Apoxis Sa |
Zastosowanie przeciwciała oraz polipeptydu
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
BR0108545A
(pt)
|
2000-02-24 |
2004-06-29 |
Xcyte Therapies Inc |
Estimulação e concentração simultâneas das células
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
JP2002060786A
(ja)
|
2000-08-23 |
2002-02-26 |
Kao Corp |
硬質表面用殺菌防汚剤
|
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
|
CA2438682A1
(en)
|
2001-02-20 |
2002-08-29 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
|
WO2003016496A2
(en)
|
2001-08-20 |
2003-02-27 |
The Scripps Research Institute |
Zinc finger binding domains for cnn
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
DK1594542T3
(da)
|
2003-02-20 |
2010-10-11 |
Seattle Genetics Inc |
Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
|
|
US20080025989A1
(en)
|
2003-02-20 |
2008-01-31 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
|
EP1460088A1
(en)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
|
DE10328289B3
(de)
|
2003-06-23 |
2005-01-05 |
Enginion Ag |
Arbeitsmedium für Dampfkreisprozesse
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7641903B2
(en)
|
2004-10-15 |
2010-01-05 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
US20120294863A1
(en)
|
2004-10-15 |
2012-11-22 |
Seattle Genetics, Inc. |
Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders
|
|
US8337838B2
(en)
|
2004-10-15 |
2012-12-25 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
EP1799262A4
(en)
|
2004-10-15 |
2009-10-21 |
Seattle Genetics Inc |
ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS
|
|
EP3530321A1
(en)
|
2004-12-10 |
2019-08-28 |
Peter MacCallum Cancer Institute |
Methods and compositions for adoptive immunotherapy
|
|
EP1871418B1
(en)
|
2005-04-19 |
2014-03-19 |
Seattle Genetics, Inc. |
Humanized anti-cd70 binding agents and uses thereof
|
|
CN103146708A
(zh)
|
2005-06-30 |
2013-06-12 |
Abbvie公司 |
Il-12/p40结合蛋白
|
|
NZ566395A
(en)
|
2005-09-26 |
2012-03-30 |
Medarex Inc |
Human monoclonal antibodies to CD70
|
|
AU2007333098A1
(en)
*
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind CD70 and uses thereof
|
|
PL2856876T3
(pl)
|
2007-03-30 |
2018-06-29 |
Memorial Sloan-Kettering Cancer Center |
Konstytutywna ekspresja ligandów kostymulujących na limfocytach T poddanych transferowi adoptywnemu
|
|
US7771720B2
(en)
|
2007-09-07 |
2010-08-10 |
Cisthera, Inc. |
Humanized PAI-1 antibodies
|
|
KR101674097B1
(ko)
|
2008-04-11 |
2016-11-08 |
시애틀 지네틱스, 인크. |
췌장, 난소 및 다른 암의 검출 및 치료
|
|
CA2729567C
(en)
|
2008-06-30 |
2018-04-24 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-cd27 antibody
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
NO2510096T3
(enExample)
|
2009-12-10 |
2015-03-21 |
|
|
|
ES2705015T3
(es)
|
2009-12-29 |
2019-03-21 |
Kyowa Hakko Kirin Co Ltd |
Anticuerpo anti-CD27
|
|
PT2542590T
(pt)
|
2010-03-05 |
2017-08-31 |
Univ Johns Hopkins |
Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
|
|
NZ602892A
(en)
|
2010-04-13 |
2014-08-29 |
Celldex Therapeutics Inc |
Antibodies that bind human cd27 and uses thereof
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
JP6023706B2
(ja)
|
2010-07-09 |
2016-11-09 |
アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． |
Ｃｄ２７に対するアゴニスト抗体
|
|
NZ723974A
(en)
|
2010-10-27 |
2017-03-31 |
Baylor College Medicine |
Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
PL2686347T3
(pl)
|
2011-03-16 |
2018-10-31 |
Argenx Bvba |
Przeciwciała przeciwko CD70
|
|
SI3415531T1
(sl)
|
2011-05-27 |
2023-12-29 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) - vezni proteini
|
|
US9382319B2
(en)
|
2011-09-26 |
2016-07-05 |
Jn Biosciences Llc |
Hybrid constant regions
|
|
US8871908B2
(en)
|
2011-11-11 |
2014-10-28 |
Rinat Neuroscience Corp. |
Antibodies specific for Trop-2 and their uses
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
KR20130060720A
(ko)
|
2011-11-30 |
2013-06-10 |
한국전자통신연구원 |
목적 기반 시맨틱 서비스 디스커버리를 위한 서비스 목적 해석 장치 및 방법
|
|
BR122020002414B1
(pt)
|
2012-03-15 |
2022-03-03 |
Janssen Biotech, Inc |
Uso de anticorpos anti-cd27 humanos
|
|
ES3065694T3
(en)
|
2012-04-11 |
2026-05-07 |
Us Health |
Chimeric antigen receptors targeting b-cell maturation antigen
|
|
EP4541818A3
(en)
|
2012-05-25 |
2025-07-23 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
ES2937015T3
(es)
|
2012-11-01 |
2023-03-23 |
Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft |
Anticuerpo contra CD269 (BCMA)
|
|
US9963513B2
(en)
|
2013-02-05 |
2018-05-08 |
Engmab Sàrl |
Method for the selection of antibodies against BCMA
|
|
WO2014158821A1
(en)
|
2013-03-12 |
2014-10-02 |
Imaginab, Inc. |
Antigen binding constructs to cd70
|
|
SG11201506372RA
(en)
|
2013-03-13 |
2015-09-29 |
Seattle Genetics Inc |
Cyclodextrin and antibody-drug conjugate formulations
|
|
WO2014140374A2
(en)
|
2013-03-15 |
2014-09-18 |
Novo Nordisk A/S |
Monovalent cd27 antibodies
|
|
EP2975942B1
(en)
|
2013-03-21 |
2018-08-08 |
Sangamo Therapeutics, Inc. |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
|
JP2016522679A
(ja)
|
2013-04-04 |
2016-08-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
|
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
|
DK3309248T3
(da)
|
2013-05-29 |
2021-08-02 |
Cellectis |
Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system
|
|
CN106459995B
(zh)
|
2013-11-07 |
2020-02-21 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
MX377283B
(es)
|
2013-11-21 |
2025-03-07 |
Ucl Business Ltd |
Célula t o nk que coexpresa un receptor antigénico quimérico (car).
|
|
CN106459915A
(zh)
|
2014-02-04 |
2017-02-22 |
凯德药业公司 |
用于治疗b细胞恶性肿瘤和其它癌症的自体t细胞的生产方法及其组合物
|
|
AU2015216875B2
(en)
*
|
2014-02-14 |
2021-02-25 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
|
US20150328292A1
(en)
|
2014-03-07 |
2015-11-19 |
Bellicum Pharmaceuticals, Inc. |
Caspase polypeptides having modified activity and uses thereof
|
|
MX373460B
(es)
|
2014-03-11 |
2020-04-07 |
Cellectis |
Metodo para generar celulas t compatibles para el trasplante alogenico.
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
CA2945620C
(en)
|
2014-04-14 |
2022-12-06 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
|
KR102595473B1
(ko)
*
|
2014-04-18 |
2023-10-30 |
에디타스 메디신, 인코포레이티드 |
암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분
|
|
US20170158749A1
(en)
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
|
CN106536564B
(zh)
*
|
2014-06-02 |
2021-08-31 |
美国卫生和人力服务部 |
靶向cd-19的嵌合抗原受体
|
|
EP3151846A4
(en)
|
2014-06-05 |
2017-12-27 |
Sangamo BioSciences, Inc. |
Methods and compositions for nuclease design
|
|
MY181834A
(en)
|
2014-07-21 |
2021-01-08 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
MX2017001079A
(es)
|
2014-07-24 |
2017-09-12 |
Bluebird Bio Inc |
Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
|
|
JP2017522884A
(ja)
|
2014-07-29 |
2017-08-17 |
ファイザー・インク |
がん免疫療法のためのＥＧＦＲｖＩＩＩ特異的キメラ抗原受容体
|
|
KR20220150428A
(ko)
|
2014-08-12 |
2022-11-10 |
안트로제네시스 코포레이션 |
림프절 b 세포 구역, 피부, 또는 위장관으로 귀소하도록 조작된 car-t 림프구
|
|
GB201418965D0
(enExample)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
KR20170075013A
(ko)
|
2014-10-31 |
2017-06-30 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Cart 세포에서 유전자 발현의 변경 및 그의 용도
|
|
EP3215623A4
(en)
|
2014-11-06 |
2018-09-26 |
President and Fellows of Harvard College |
Cells lacking b2m surface expression and methods for allogeneic administration of such cells
|
|
WO2016089433A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
|
SG11201704549UA
(en)
|
2014-12-05 |
2017-07-28 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
EP3230310B1
(en)
*
|
2014-12-08 |
2019-06-12 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Anti-cd70 chimeric antigen receptors
|
|
EP3971210A1
(en)
|
2014-12-12 |
2022-03-23 |
2seventy bio, Inc. |
Composition for use in the treatment of b cell related conditions in a subject in need thereof comprisine an effector cell comrising a bcma chimeric antigen receptors
|
|
KR102923234B1
(ko)
|
2014-12-19 |
2026-02-04 |
다나-파버 캔서 인스티튜트 인크. |
키메라 항원 수용체 및 이의 사용 방법
|
|
WO2016120218A1
(en)
|
2015-01-26 |
2016-08-04 |
Cellectis |
ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY
|
|
GB201504840D0
(en)
|
2015-03-23 |
2015-05-06 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
AU2016243583B2
(en)
|
2015-03-27 |
2022-03-10 |
President And Fellows Of Harvard College |
Modified T cells and methods of making and using the same
|
|
KR102888521B1
(ko)
|
2015-04-06 |
2025-11-19 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
|
|
WO2016174652A1
(en)
|
2015-04-30 |
2016-11-03 |
Technion Research & Development Foundation Limited |
Chimeric antigen receptors and methods of their use
|
|
CA2988854A1
(en)
|
2015-05-08 |
2016-11-17 |
President And Fellows Of Harvard College |
Universal donor stem cells and related methods
|
|
BR112017024757A2
(pt)
|
2015-05-18 |
2018-11-13 |
TCR2 Therapeutics Inc. |
composições e métodos para reprogramação de tcr utilizando proteínas de fusão
|
|
CN104910278B
(zh)
|
2015-05-27 |
2018-05-25 |
上海吉凯基因科技有限公司 |
一种用于制备cart细胞的具有高效转染能力和生物学活性的慢病毒
|
|
GB2557123B
(en)
|
2015-07-31 |
2021-11-03 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
WO2017058850A1
(en)
|
2015-09-28 |
2017-04-06 |
Regents Of The University Of Minnesota |
Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity
|
|
EP4108255A1
(en)
|
2015-10-05 |
2022-12-28 |
Precision Biosciences, Inc. |
Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
|
|
GB201518136D0
(en)
|
2015-10-14 |
2015-11-25 |
Glaxosmithkline Ip Dev Ltd |
Novel chimeric antigen receptors
|
|
WO2017070429A1
(en)
|
2015-10-22 |
2017-04-27 |
Regents Of The University Of Minnesota |
Methods involving editing polynucleotides that encode t cell receptor
|
|
WO2017075537A1
(en)
|
2015-10-30 |
2017-05-04 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
AU2016353067B2
(en)
|
2015-11-13 |
2023-10-05 |
Sanford Research |
Anti-BCMA polypeptides and proteins
|
|
CN108699557B
(zh)
|
2015-12-04 |
2025-08-15 |
诺华股份有限公司 |
用于免疫肿瘤学的组合物和方法
|
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
|
ES2983043T3
(es)
|
2015-12-18 |
2024-10-21 |
Sangamo Therapeutics Inc |
Alteración dirigida del receptor de células T
|
|
AU2016374253B2
(en)
|
2015-12-18 |
2021-10-21 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the MHC cell receptor
|
|
CA3009637A1
(en)
|
2015-12-23 |
2017-06-29 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
|
|
ITUB20160112A1
(it)
|
2016-01-28 |
2016-04-28 |
Serteaweb Srl |
Processo di allarme e sistema televisivo relativo ad un tale processo di allarme
|
|
IL311107A
(en)
|
2016-02-17 |
2024-04-01 |
Seagen Inc |
BCMA antibodies and their use for the treatment of cancer and immune disorders
|
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
AU2017230011A1
(en)
|
2016-03-11 |
2018-09-27 |
2Seventy Bio, Inc. |
Genome edited immune effector cells
|
|
US10603380B2
(en)
|
2016-04-01 |
2020-03-31 |
Kite Pharma, Inc. |
Chimeric antigen and T cell receptors and methods of use
|
|
EP3436059B1
(en)
|
2016-04-01 |
2022-01-12 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Use of chimeric antigen receptor modified cells to treat cancer
|
|
CA3020330A1
(en)
|
2016-04-07 |
2017-10-12 |
Bluebird Bio, Inc. |
Chimeric antigen receptor t cell compositions
|
|
WO2017180993A1
(en)
|
2016-04-14 |
2017-10-19 |
Bluebird Bio, Inc. |
Salvage chimeric antigen receptor systems
|
|
WO2017182608A1
(en)
|
2016-04-22 |
2017-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions for the treatment of b-cell malignancies
|
|
US11141471B2
(en)
|
2016-04-25 |
2021-10-12 |
Regen BioPharma, Inc. |
Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells
|
|
US10875919B2
(en)
|
2016-04-26 |
2020-12-29 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2017186928A1
(en)
|
2016-04-29 |
2017-11-02 |
Curevac Ag |
Rna encoding an antibody
|
|
CN116850305A
(zh)
|
2016-05-06 |
2023-10-10 |
朱诺治疗学股份有限公司 |
基因工程化细胞及其制备方法
|
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
US12048718B2
(en)
|
2016-06-07 |
2024-07-30 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft |
Chimeric antigen receptor and CAR-T cells that bind BCMA
|
|
JP7114490B2
(ja)
|
2016-06-24 |
2022-08-08 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
CN106544321B
(zh)
|
2016-10-13 |
2019-01-29 |
北京艺妙神州医疗科技有限公司 |
通用型car-t细胞及其制备方法和用途
|
|
WO2018068257A1
(zh)
|
2016-10-13 |
2018-04-19 |
北京艺妙神州医疗科技有限公司 |
通用型car-t细胞及其制备方法和用途
|
|
WO2018073393A2
(en)
*
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
WO2018073391A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
|
AU2018208614A1
(en)
|
2017-01-10 |
2019-07-11 |
The General Hospital Corporation |
Modified T cells and methods of their use
|
|
BR112019023608A2
(pt)
*
|
2017-05-12 |
2020-05-26 |
Crispr Therapeutics Ag |
Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
|
|
WO2019119036A1
(en)
*
|
2017-12-19 |
2019-06-27 |
Benitec Biopharma Limited |
Cd70 deficient cells, and methods and reagents for producing same
|
|
TW201936633A
(zh)
|
2018-02-01 |
2019-09-16 |
美商輝瑞大藥廠 |
標靶至cd70的嵌合抗原受體
|
|
US11957695B2
(en)
*
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|